Business
CytoSorbents to Report Second Quarter 2023 Operating and Financial Results
PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the
About this update from Cytosorbents Corporation
[{"type":"text","content":"PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2023 operating and financial results after the market close on Tuesday, August 1st, 2023. CytoSorbents’ management will host a live presentation webcast and a question and answer session at 4:30PM EDT the same day. Webcast Details:Date: Tuesday, August 1st, 2023Time: 4:30 PM Eastern Webcast link: https://edge.media-server.com/mmc/p/ux9gjyvu Conference Call Details:For those participants who cannot join by webcast, we are pleased to offer a conference call option accessible through the following link: https://register.vevent.com/register/BIb5f023a4734446ce8e778065c2d484d9 Click on the call link and complete the online registration form.Upon registering you will receive the dial-in info and a unique PIN to join the call, as well as an email confirmation with the details.Select a method for joining the call. Dial-In: A dial in number and unique PIN are displayed to connect directly from your phone.Call Me: Enter your phone number and click “Call Me” for an immediate callback from the system. For either the webcast or conference call, it is recommended that participants log or dial in approximately 10 minutes prior to the start of the call. An archived recording and written transcript of the conference call will be available under the Investor Relations section of the Company’s website at http://cytosorbents.com/investor-relations/financial-results/ About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb®, is approved in the European Union and distributed in 75 countries worldwide. It is an extracorporeal cytokine adsorber that reduces \"cytokine storm\" or \"cytokine release syndrome\" in common critical illnesses that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators t...